# Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus

> **NCT05359432** · PHASE4 · COMPLETED · sponsor: **Getz Pharma** · enrollment: 120 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Vildagliptin

## Key facts

- **NCT ID:** NCT05359432
- **Lead sponsor:** Getz Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-01
- **Primary completion:** 2021-08-10
- **Final completion:** 2021-08-18
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2022-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05359432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05359432, "Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05359432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*